Literature DB >> 7773301

Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.

S L Wang1, J Huang, M D Lai, J J Tsai.   

Abstract

Cytochrome P450 (CYP) 2C9 catalyses the metabolism of a wide range of drugs. Previous studies have shown the differences in the amino acid composition among CYP2C9 variants at Cys144/Arg, Tyr358/Cys, Leu359/Ile, and Gly417/Asp. PCR-endonuclease digestion methods have been developed to detect these four possible polymorphisms. The T416-->C mutation in exon 3 of CYP2C9 (Cys144-->Arg) creates an Ava II site. In the 135 subjects we tested, all leukocyte DNA samples showed a complete Ava II digestion indicating homozygous C416 (Arg144). A Tyr358-->Cys mutation will create a Nsi I site at codon 1057-1063 in exon 7. In 40 subjects tested, all samples showed negative results. DNA sequencing on a few samples showed Tyr358Ile359. A mismatched PCR primer pair was then designed to detect codon C1061-->A (Leu359-->Ile) mutation. In 115 subjects tested, 111 samples showed a complete Nsi I digestion (Ile359) and four samples showed heterozygous results. Another mismatched PCR primer pair was used to confirm the C1061 codon in heterozygous subjects. The four heterozygous subjects showed partial digestion with endonuclease Kpn I, which confirmed the heterozygous Ile/Leu at amino acid 359. The G1236-->A mutation in exon 8 of CYP2C9 (Gly417-->Asp) creates a Hph I site. In all 46 subjects, homozygous G1236 (Gly417) was found. Most Chinese subjects actually have Arg144 Tyr358 Ile359 Gly417 in CYP2C9 as previously reported human-2. Furthermore, we found an A-->T (+12 position in intron 2) mutation in our CYP2C9 sequencing process. The mutation creates a NIa III site.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773301     DOI: 10.1097/00008571-199502000-00004

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  41 in total

1.  CYP2C9 polymorphism and warfarin dose requirements.

Authors:  Ann K Daly; Christopher P Day; Guruprasad P Aithal
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

2.  CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.

Authors:  Joyce A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

3.  Allele and genotype frequency of CYP2C9 in Tamilnadu population.

Authors:  C Adithan; N Gerard; S Vasu; R Balakrishnan; C H Shashindran; R Krishnamoorthy
Journal:  Eur J Clin Pharmacol       Date:  2003-09-19       Impact factor: 2.953

4.  Genetic polymorphism of the CYP2C9 subfamily of 3 different races in warfarin maintenance dose.

Authors:  Gin Gin Gan; Maude Elvira Phipps; Chee Seng Ku; Alan Teh; Vijaya Sangkar
Journal:  Int J Hematol       Date:  2004-10       Impact factor: 2.490

5.  Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population.

Authors:  Al-Motassem Yousef; Nailya R Bulatova; William Newman; Nancy Hakooz; Said Ismail; Hisham Qusa; Farah Zahran; Nidaa Anwar Ababneh; Farah Hasan; Imad Zaloom; Ghada Khayat; Rawan Al-Zmili; Randa Naffa; Ola Al-Diab
Journal:  Mol Biol Rep       Date:  2012-06-22       Impact factor: 2.316

6.  A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Authors:  Su-Jun Lee; Yin Jin Jang; Eun-Young Cha; Ho-Sook Kim; Sang Seop Lee; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

7.  Allele and genotype frequencies of CYP2C9 in a Korean population.

Authors:  Jung-Woo Bae; Hyun-Kyung Kim; Ji-Hong Kim; Sang-In Yang; Mi-Jeong Kim; Choon-Gon Jang; Young-Seo Park; Seok-Yong Lee
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

Review 8.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

9.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.

Authors:  Yifan Zhang; Dayong Si; Xiaoyan Chen; Nan Lin; Yingjie Guo; Hui Zhou; Dafang Zhong
Journal:  Br J Clin Pharmacol       Date:  2007-02-12       Impact factor: 4.335

10.  CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers.

Authors:  Pedro Dorado; Roland Berecz; Maria-Jesús Norberto; Umit Yasar; Marja-Liisa Dahl; Adrián LLerena
Journal:  Eur J Clin Pharmacol       Date:  2003-05-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.